We have observed the innovation and growth demonstrated by EDI over the years and welcome the opportunity to combine the strengths of EDI’s technology and manufacturing with the W.H.P.M. family of companies.
IRWINDALE, Calif. (PRWEB) September 27, 2018
Carehealth America Corporation, an affiliate of W.H.P.M., Inc., today announced it has acquired all of the assets of Express Diagnostics Int’l, Inc., including all products, processes, and intellectual property. Express Diagnostics was founded in 2004 to manufacture and distribute drugs of abuse testing devices worldwide under the DrugCheck® label, one of the most recognized brands in the industry. W.H.P.M., founded in 1993, is a global leader in the research, development, and manufacture of the most advanced and innovative one-step membrane tests and medical diagnostic devices on the market today.
With the acquisition by W.H.P.M. affiliate Carehealth America Corp., customer and distributor partners of Express Diagnostics Int’l (EDI) will benefit from the companies’ complimentary technologies and intellectual property, including W.H.P.M.’s advanced biotech research and development capabilities. EDI customers will also now have access to a wider range of products, including additional oral fluid and CLIA-waived devices, as well as expanded product development opportunities via Carehealth America Corp. and W.H.P.M.
“We are pleased to announce this acquisition,” says Dr. John Wan, founder and President of W.H.P.M., Inc. “We have observed the innovation and growth demonstrated by EDI over the years and welcome the opportunity to combine the strengths of EDI’s technology and manufacturing with the W.H.P.M. family of companies. With these additional capabilities, we’ll continue working to deliver advanced, rapid diagnostics worldwide to reduce healthcare costs, help our distribution partners, and improve people’s lives.”
Central to the decision to acquire the assets of EDI was the opportunity to augment W.H.P.M.’s substantial catalog of intellectual property (IP). The addition of EDI’s patents, trademarks, and copyrights to the W.H.P.M. portfolio offers significant competitive advantages and potential for growth. This complimentary IP now owned by W.H.P.M., specifically patents, will continue to be defended.
“W.H.P.M. and Carehealth look forward to continuing to serve EDI’s customers with the same product line and quality they previously enjoyed,” adds Dr. Wan. “As we build on both our growth strategy and EDI’s U.S. manufacturing capabilities, we will implement systems and processes to distribute products more efficiently and consistently worldwide while making them accessible to more customers.”
About W.H.P.M., Inc.
W.H.P.M. Inc., established in 1993, is a privately-held corporation headquartered in Irwindale, Calif. The W.H.P.M. family of companies is a global leader in the research, development, and deployment of the most advanced and innovative one-step membrane tests and medical diagnostics devices on the market today. Designated an FDA-registered cGMP facility for in vitro diagnostic medical devices, W.H.P.M. offers customers a variety of fast-turnaround services for rapid diagnostics, including OEM production, customized assembly, and private labeling. It assists companies in rapidly producing a wide array of products by utilizing its extensive experience in advanced bio-technology and design/manufacturing systems. Learn more at whpm.com.
About Express Diagnostics Int’l, Inc.
Express Diagnostics Int’l was founded in 2004. As the FDA-registered and ISO 13485:2003-certified U.S. manufacturer of DrugCheck® onsite drugs of abuse screening devices, the company was named three times to the Inc. 5000 list of fastest growing companies in the U.S. Learn more at drugcheck.com.